Clinical Trial Update: Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial investigating anlotinib combined with docetaxel versus docetaxel alone in previously treated advanced non-small cell lung cancer (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Yong Fang | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN